Literature DB >> 4655269

Effect of chronic drug treatment on intestinal membrane transport of 14 C-L-dopa.

L Rivera-Calimlim.   

Abstract

1. By the use of the everted jejunal sac it was shown that chronic oral treatment of rats with various drugs can either increase or decrease the mucosal transport of (14)C-L-DOPA or alter its serosal/tissue ratio.2. (14)C-L-DOPA transport was significantly increased in rats that were chronically treated with L-DOPA and diminished in those that were treated with chlorpromazine and phenobarbitone.3. Chronic treatment with amantadine and neomycin did not affect (14)C-L-DOPA intestinal transport, although direct addition of amantadine to the medium, significantly increased (14)C-L-DOPA transport in everted sacs of nontreated rats. Addition of neomycin directly to the medium did not affect (14)C-L-DOPA transport.4. The possible mechanisms of these findings and their clinical significance are discussed.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4655269      PMCID: PMC1666371          DOI: 10.1111/j.1476-5381.1972.tb06895.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  17 in total

Review 1.  ON THE METABOLISM AND ACTION MECHANISM OF THE PHENOTHIAZINE DRUGS.

Authors:  I S FORREST; F M FORREST
Journal:  Exp Med Surg       Date:  1963

2.  Action of some phenothiazine derivatives on the respiratory chain.

Authors:  M J DAWKINS; J D JUDAH; K R REES
Journal:  Biochem Pharmacol       Date:  1959-08       Impact factor: 5.858

3.  The use of sacs of everted small intestine for the study of the transference of substances from the mucosal to the serosal surface.

Authors:  T H WILSON; G WISEMAN
Journal:  J Physiol       Date:  1954-01       Impact factor: 5.182

4.  Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinson's disease.

Authors:  L O Farnebo; K Fuxe; M Goldstein; B Hamberger; U Ungerstedt
Journal:  Eur J Pharmacol       Date:  1971-09       Impact factor: 4.432

Review 5.  Absorption of protein digestion products: a review.

Authors:  D M Matthews; L Laster
Journal:  Gut       Date:  1965-10       Impact factor: 23.059

6.  Absorption and metabolism of L-dopa by the human stomach.

Authors:  L Rivera-Calimlim; C A Dujovne; J P Morgan; L Lasagna; J R Bianchine
Journal:  Eur J Clin Invest       Date:  1971-05       Impact factor: 4.686

7.  L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects.

Authors:  M D Muenter; G M Tyce
Journal:  Mayo Clin Proc       Date:  1971-04       Impact factor: 7.616

8.  Distribution and properties of amino acid decarboxylases in gastric mucosa.

Authors:  R Håkanson; C Owman
Journal:  Biochem Pharmacol       Date:  1966-04       Impact factor: 5.858

9.  Malabsorption of folic acid due to diphenylhydantoin.

Authors:  M B Dahlke; E Mertens-Roesler
Journal:  Blood       Date:  1967-09       Impact factor: 22.113

10.  High doses of neomycin sulfate and the absorption of glucose and xylose from the rat small intestine.

Authors:  M D Small; V Folen; G Abrams; F Bledsoe; H T Norris; H Sprinz
Journal:  Am J Dig Dis       Date:  1966-12
View more
  3 in total

Review 1.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

2.  Impaired absorption of chlorpromazine in rats given trihexyphenidyl.

Authors:  L Rivera-Calimlim
Journal:  Br J Pharmacol       Date:  1976-03       Impact factor: 8.739

Review 3.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.